

Original Research

Melatonin ameliorates cisplatin-induced asthenozoospermia via reducing oxidative stress

Yunpeng Shao¹, Qiao Zhou², Jun Xue^{1,3}, Baixin Shen¹, Juan Ji^{2,*}, Zhongqing Wei^{1,*}¹Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, 210011 Nanjing, Jiangsu, China²Department of Reproduction, The Affiliated Obstetrics and Gynecology Hospital with Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, 210029 Nanjing, Jiangsu, China³Department of Reproduction, The Second Affiliated Hospital of Nanjing Medical University, 210011 Nanjing, Jiangsu, China*Correspondence: jjuan_19@163.com (Juan Ji); Weizq1@163.com (Zhongqing Wei)

Submitted: 16 July 2021 Accepted: 17 August 2021 Published: 26 September 2021

Abstract

Background and objective: Cisplatin is an alkylating agent that has become a first-line therapy for some tumors. However, overproduction of reactive oxygen species (ROS) by cisplatin can cause male infertility, which can affect patients' quality of life. Melatonin, which has the ability to provide resistance against oxidation, is a potential therapy for male infertility caused by cisplatin. **Material and methods:** Normal human spermatozoa samples were divided into (i) control group incubated with physiological saline solution; (ii) cisplatin group incubated with cisplatin; (iii) melatonin group incubated with melatonin; and (iv) melatonin + cisplatin group incubated with melatonin and cisplatin. Spermatozoa motility was measured using a computer-aided semen analysis system. Additionally, we determined spermatozoa apoptosis through terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling. The mitochondrial membrane potential ($\Delta\Psi_m$) and levels of ATP, ROS, and malondialdehyde, as a metabolite of oxidative stress, were measured to study the mechanism by which melatonin can protect human spermatozoa. **Results:** Melatonin improved sperm motility, and decreased apoptosis and increased the $\Delta\Psi_m$ value and level of ATP in sperm. More importantly, the overproduction of ROS induced by cisplatin was reduced by melatonin. Furthermore, western blotting revealed that melatonin increased the expression of antioxidant pathway components nuclear factor erythroid 2-related factor (Nrf2) and heme oxygenase-1 (HO-1) that was reduced by cisplatin. **Conclusion:** Our studies suggested that melatonin might protect human spermatozoa against the effects of cisplatin through Nrf2/HO-1.

Keywords: Asthenozoospermia; Melatonin; Cisplatin; Sperm motility; ROS; Human sperm; Nrf2

1. Introduction

Cisplatin is one of several platinum-based anticancer agents and is used for the treatment of many types of tumors, including solid tumors, ovarian, breast, brain, kidney, testicular, and head and neck tumors, as well as leukemia [1]. However, cisplatin has severe side effects on male fertility, which can remarkably affect patients' quality of life [2]. Infertility induced by cisplatin is believed to be associated with the overproduction of reactive oxygen species (ROS) and increased levels of hydroxyl radicals (OH^-), hydrogen peroxide (H_2O_2), and superoxide anions (O_2^-), which in turn can cause oxidative damage (both *in vitro* and *in vivo*) [2]. This oxidative damage is the result of free radical-mediated chain reactions that leads to the oxidation of nucleic acids, such as DNA and RNA, lipid peroxidation, and protein oxidation [2]. Cells maintain a normal level of free radicals for cellular processes through endogenous enzymatic and non-enzymatic antioxidants. If the balance between the generation and degradation of free radicals is upset, a situation known as oxidative stress, damage to the cells can occur [3].

Sperm are known to possess a high content of polyunsaturated fatty acids, plasmalogens, and sphingomyelins, making sperm sensitive to oxidative stress [4]. Besides,

lipids in sperm are easily oxidized, which can cause severe damage to the sperm [5]. Cisplatin can also induce a mitochondrial-dependent radical response, which can damage nuclear DNA, enhancing the cytotoxic effect. The dysfunction of mitochondria induced by cisplatin varies among cells, depending on the mitochondrial redox status, mitochondrial DNA integrity, as well as bioenergetic function of the cells [6]. Mature human sperm have 22–28 mitochondria helically arranged around the axoneme of the sperm, which generate ROS and ATP to maintain sperm motility. These mitochondria are potential targets of cisplatin [7,8]. Therefore, it is desirable to find an effective therapy to protect sperm against cisplatin.

Melatonin is mainly produced by the pineal gland and plays major role in stimulating antioxidant enzymes and scavenging free radicals [4,9,10]. In many cell types, the nuclear factor erythroid 2-related factor (Nrf2) functions as antioxidant factor through the regulation of downstream genes, especially heme oxygenase-1 (HO-1) [11]. It has been reported that melatonin can promote the activation of Nrf2 and the expression of the antioxidant enzyme HO-1 [12]. However, it remains unknown whether melatonin can protect sperm against cisplatin. Therefore, in the present study, we investigated the effects of melatonin on human



sperm characteristics and biochemistry as related to oxidative stress and a mechanism for the prevention of damage caused by cisplatin.

2. Materials and methods

2.1 Chemicals

Cisplatin and melatonin were purchased from Sigma (St. Louis, MO, USA).

2.2 Human biological samples

Sixty-six ejaculated sperm samples with $\geq 15 \times 10^6$ spermatozoa mL^{-1} , $\geq 32\%$ progressive sperm, and $\geq 4\%$ morphologically normal forms were obtained from healthy donors undergoing routine semen analysis in the Second Affiliated Hospital of Nanjing Medical University (Nanjing, China). Then, the sperm samples were pooled and divided equally into each group in the trials and each experiment was repeated three times. The study was approved by the Ethics Committee of the Second Affiliated Hospital of Nanjing Medical University and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Donors were informed about the purpose of the study and their consent was obtained.

2.3 Sperm preparation and treatment

Stock solutions of cisplatin dissolved in physiological saline were stored at -20°C and diluted to $25 \mu\text{mol}\cdot\text{L}^{-1}$, $250 \mu\text{mol}\cdot\text{L}^{-1}$, $2.5 \text{mmol}\cdot\text{L}^{-1}$, $25 \text{mmol}\cdot\text{L}^{-1}$, and $50 \text{mmol}\cdot\text{L}^{-1}$. As a control, sperm suspensions were diluted in physiological saline. Stock solutions of melatonin dissolved in dimethyl sulfoxide (DMSO) were stored at 4°C and diluted with sperm solutions to final concentrations of 5, 12.5, 50, 100, and 500 $\text{mmol}\cdot\text{L}^{-1}$ ($\text{pH} = 7.4$). Sperm were collected by density gradient preparation. Sperm suspensions were diluted with fresh human tubal fluid (HTF) (with 10% BSA) to yield an approximate concentration of 1×10^6 sperm mL^{-1} . The samples were centrifuged, and motile sperm were resuspended in HTF containing cisplatin or melatonin at different concentrations. The sperm suspensions were incubated for 3 h at 37°C in a humidified atmosphere according to the protocol as described in a previous report [13].

2.4 Assessment of sperm motility

Sperm motility was analyzed using computer assisted sperm analysis (CASA) as described previously [14]. An aliquot of $10 \mu\text{L}$ of each sample was transferred to a Maker chamber that had been prewarmed to 37°C . The motility of 200 spermatozoa was evaluated by CASA.

2.5 TUNEL assay

For each sample, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay was performed according to the manufac-

turer's protocol (Vazyme, Nanjing, China) to determine the apoptotic sperms, and 200 sperms were counted in a defined area on every slide. Slides were observed using an LSM710 confocal microscope (Carl Zeiss, Oberkochen, Germany), driven by ZEN2009 software (Carl Zeiss, Oberkochen, Germany).

2.6 Measurement of mitochondrial membrane potential

The fluorescent, lipophilic and cationic probe, JC-1, was used to measure the $\Delta\Psi_{\text{m}}$ value of human sperm according to the manufacturer's directions. Briefly, after the indicated treatments, the sperm samples were incubated with JC-1 staining solution ($5 \mu\text{g}\cdot\text{mL}^{-1}$) for 20 min at 37°C . The sperm samples were then rinsed twice with washing buffer and the fluorescence intensity of both mitochondrial JC-1 monomers (520 nm) and aggregates (590 nm) were detected using cytometry (BD Biosciences, San Diego, CA, USA). The samples were shielded from light during the incubation with the JC-1 staining solution.

2.7 Measurement of ATP production

ATP levels were measured using an ATP assay kit (Beyotime Institute of Biotechnology, Shanghai, China) according to the manufacturer's instructions. Briefly, 1×10^6 sperms were lysed using ATP lysis buffer on ice. Samples were collected and centrifuged at 12,000 rpm for 10 min at 4°C to acquire the supernatants for further analysis. Samples and ATP detection working dilution were added and the luminescence activity was measured immediately using a luminometer (Bio Tek, Winooski, VT, USA).

2.8 ROS measurement

Approximately 1×10^6 sperms were collected, washed with serum-free HTF culture medium, and incubated with $5 \mu\text{mol}\cdot\text{L}^{-1}$ dihydroethidium at 37°C for 30 min. Then, the sperms were harvested, washed, and resuspended in serum-free HTF culture medium. DHE fluorescence distribution was recorded by cytometry.

2.9 Malondialdehyde (MDA) assessment

Each sample was mixed with 20% trichloroacetic acid and 0.67% thiobarbituric acid, and the mixture was incubated at 100°C for 15 min. The precipitate that resulted upon cooling was removed by centrifugation ($1600 \times g$, 15 min). The fluorescence in the organic phase was measured at 532 nm using a fluorescence spectrophotometer, and the results were expressed as μmol MDA per mg protein.

2.10 Western blot analysis

Proteins were extracted from the human sperms. The expression of Nrf2 and HO-1 was examined by western blot. β -Actin was used as the internal loading control of protein. The protein samples were separated by electrophoresis on SDS/PAGE and transferred to PVDF membranes (Millipore, Marlborough, MA, USA). Each mem-




Fig. 1. Melatonin significantly restored human sperm motility. (a) Sperms were incubated with different concentrations of cisplatin for 3 h. The figure shows total sperm motility (a–c) and progressive motility. *** $p < 0.001$, ** $p < 0.01$, and * $p < 0.05$ compared with the control. (b,c) Sperms were incubated with only cisplatin, or different concentrations of melatonin plus 250 μ M cisplatin for 3 h. The figure shows (b) total sperm motility (a–c) and (c) progressive motility. *** $p < 0.001$, ** $p < 0.01$, and * $p < 0.05$ compared with the control.

brane was blocked with 5% nonfat milk and incubated overnight at 4 °C with the appropriate primary antibodies (anti-Nrf2, anti-HO-1, anti- β -Actin) followed by incubation with suitable secondary antibodies for 2 h at room temperature. The signals from the detected proteins were visualized.

2.11 Statistical analysis

Statistical analysis was performed using SPSS 19.0 statistical software (IBM Corp., Chicago, IL, USA). All values are presented as the mean \pm SD. Statistical analyses were performed by ANOVA, followed by LSD multiple comparisons where appropriate. Variables were checked for normal distribution, and comparisons between the different concentrations and controls were carried out by paired t -tests.

3. Results

3.1 Melatonin significantly restored human sperm motility

Different concentrations of cisplatin (25 μ M, 250 μ M, 2.5 mM, 25 mM, and 50 mM) were incubated with human sperm for 3 h (Fig. 1a). Both the total and progressive motility of sperm treated with cisplatin were reduced in a dose-dependent manner ($p < 0.05$) compared with the control group. Treatment with 250 μ M cisplatin reduced the total motility by 50% compared with the control (Fig. 1a). Then, a working concentration of 250 μ M cisplatin was selected, on the basis of a previous report [15], for use in combination with human sperm and different concentrations of melatonin. Our experimental results showed that only 100 mM melatonin could restore cisplatin-induced sperm dysfunction, and 5, 12.5, and 50 mM melatonin could not recover either total motility or progressive motility (Fig. 1b,c). Also, incubation with 500 mM melatonin inhibited sperm motility (Fig. 1b,c).




Fig. 2. Melatonin decreased cisplatin-induced spermatozoa apoptosis. The effect of melatonin on spermatozoa apoptosis was investigated. Microscopic images of human spermatozoa stained with terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate-biotin nick end labeling (TUNEL) (a–d). Scale bar = 50 μm (magnification: 10×). (e) Statistical results of TUNEL staining. Control: Spermatozoa were treated with physiological saline; Cisplatin: Spermatozoa were treated with 250 μm cisplatin; Melatonin: Spermatozoa were treated with 100 mM melatonin; Melatonin + Cisplatin: Spermatozoa were treated with 100 mM melatonin and 250 μm cisplatin. *** $p < 0.001$ compared with the control or cisplatin group. Results are expressed as mean ± SD.




Fig. 3. Melatonin restored mitochondrial function. The mitochondria functions of spermatozoa were measured, including (a–e) measurement of mitochondrial membrane potential by a cytometry technique and (f) ATP production by spermatozoa from different groups. Control: Spermatozoa were treated with physiological saline; Cisplatin: Spermatozoa were treated with 250 μM cisplatin; Melatonin: Spermatozoa were treated with 100 μM melatonin; Melatonin + Cisplatin: Spermatozoa were treated with 100 μM melatonin and 250 μM cisplatin. * $p < 0.05$, *** $p < 0.001$ compared with the control or cisplatin group.

3.2 Melatonin decreased cisplatin-induced sperm apoptosis

TUNEL staining was used for the evaluation of sperm apoptosis. We found that the number of TUNEL-positive

sperms in the melatonin + cisplatin group was higher than that in the control group ($p < 0.001$), but lower than that in the cisplatin group (Fig. 2).




Fig. 4. Melatonin ameliorated oxidative stress induced by cisplatin. The effects of melatonin on sperm antioxidant levels and oxidative status were investigated, including (a–e) SOD activity and (f) MDA activity. Control: Sperms were treated with physiological saline; Cisplatin: Sperms were treated with 250 μm cisplatin; Melatonin: Sperms were treated with 100 mM melatonin; Melatonin + Cisplatin: Sperms were treated with 100 mM melatonin and 250 μm cisplatin. ****p* < 0.001 compared with the control or cisplatin group; results are expressed as mean ± SD.




Fig. 5. Melatonin improved antioxidant gene expression decreased by cisplatin. (a) Nrf2 and HO-1 protein levels were analyzed by western blotting. (b) Each data point was calculated from three triplicate groups and the data are presented as the mean \pm SD. * $p < 0.05$ compared with the control.

3.3 Melatonin restored mitochondrial function

There were fewer sperms with low $\Delta\Psi_m$ in the melatonin + cisplatin group than in the cisplatin group (Fig. 3a–d). Cisplatin treatment reduced the level of ATP compared with that of the control group ($p < 0.05$), while the ATP level in human sperm in the melatonin + cisplatin group was increased compared with the cisplatin group ($p < 0.05$) (Fig. 3e,f).

3.4 Melatonin ameliorated oxidative stress induced by cisplatin

As shown in Fig. 4, the levels of MDA and ROS in sperms were markedly increased in the cisplatin group compared those in the control group. However, the levels of MDA and SOD in the sperms were decreased in the melatonin + cisplatin group compared with the cisplatin group.

3.5 Melatonin improved antioxidant gene expression decreased by cisplatin

Our results showed that cisplatin exposure repressed the expression of the antioxidant pathway components Nrf2

and HO-1. Treatment with melatonin activated the Nrf2 and HO-1 expression reduced by cisplatin (Fig. 5a,b).

4. Discussion

Cisplatin is an effective anticancer drug, but it has demonstrated toxicity to the bladder [15], inner ear [16], peripheral nerves [17], and reproductive system [15]. Melatonin is capable of attenuating testis toxicity induced by microwave radiation [18], 2-bromopropane [19], and busulfan [20]; thus, melatonin may be useful in preventing the effect of cisplatin-induced toxicity on fertility. Although cisplatin has been shown to induce damage in the early stage of spermatogenesis in human and animal models [21,22], considering the difficulty of the application of melatonin in humans, we used ejaculated human sperm as our model to examine the effect of melatonin on fertility.

In our study, we demonstrated that cisplatin can adversely affect the motility of human sperm, which was consistent with previous reports [8]. Furthermore, we showed that a low dose of melatonin markedly alleviated the observed decrease in the motility of human sperm caused by cisplatin. However, when the melatonin dose exceeded 100 mM, melatonin itself inhibited human sperm motility. The reasons for this effect remain unknown. Considering the existence of the blood-testis barrier and the severe toxicity of potent metabolites formed from cisplatin, 100 nM melatonin could be viewed as a reference for clinical treatment.

Mitochondria, which are arranged around the mid-piece axoneme of human sperm, are the primary targets of drugs and the cause of human sperm death. The motility of human sperm is mainly maintained by mitochondria, which have important role in the generation of ATP as the molecular motor generating power for sperm flagellar movement. To further understand the cause of reduced human sperm motility, we examined the $\Delta\Psi_m$ values of sperm and found that the $\Delta\Psi_m$ value was decreased in the cisplatin group compared with that in the control group. Melatonin ameliorated the observed reduction in the $\Delta\Psi_m$ values of human sperm caused by cisplatin. Therefore, the ability of melatonin to rescue the $\Delta\Psi_m$ might explain why melatonin was able to decrease the apoptosis in sperms induced by cisplatin.

The disruption of the $\Delta\Psi_m$ might be attributed to the generation of excess ROS by human sperm mitochondria [23,24]. ROS include superoxide anions (O_2^-), hydrogen peroxide (H_2O_2), and hydroxyl radicals (OH), which are involved in many clinical disorders, including infertility [25]. Under physiological conditions, a balance exists between ROS and antioxidants in sperms. At the proper concentrations, ROS are very important for sperm motility [26]. A previous study has reported that O_2^- triggered both hyperactivation and capacitation, while superoxide dismutase, an enzyme that catalyzes the dismutation of O_2^- into oxygen and H_2O_2 , blocked these activities [27]. We showed that melatonin could reduce the levels of cisplatin-induced ROS

in sperm, suggesting that melatonin might improve mitochondrial function by reducing ROS generation. These results are consistent with a previous report that melatonin could stimulate the effect of indole on ATP production at the mitochondrial level in rats [4]. In addition to mitochondria, lipid membranes are also considered to be targets of ROS. Sperm membranes possess many polyunsaturated lipids, which are sensitive to ROS and oxidative damage, leading to fast intracellular ATP loss. The results of the present study suggested that melatonin might function as an antioxidant to rescue sperm motility by reducing ROS generation.

MDA is a major product of the lipid peroxidation of membrane polyunsaturated fatty acids. In the present study, cisplatin increased the MDA levels in human sperm compared with the control group, while these cisplatin-induced MDA increases were reduced by melatonin, further indicating that melatonin may be able to protect sperm from the effects of cisplatin.

In addition, we showed that melatonin upregulated the levels of the antioxidant factor Nrf2 and HO-1, indicating that melatonin might protect human sperm through activating Nrf2 and its downstream gene HO-1.

5. Conclusions

In summary, melatonin, as antioxidant, can protect against the cisplatin-induced toxicity of human sperm, providing a new strategy for treating clinical infertility. However, a lack of research into the effects of melatonin in the early stage of human spermatogenesis currently limits the use of melatonin in the treatment of cisplatin-induced testis toxicity in the clinic. However, the present study indicates that using melatonin may be a useful strategy in the prevention of cisplatin-induced testis toxicity.

Abbreviations

ATP, adenosine triphosphate; ROS, reactive oxygen species; Nrf2, nuclear factor erythroid 2-related factor; HO-1, heme oxygenase-1; DMSO, dimethyl sulfoxide; HTF, human tubal fluid; CASA, computer-assisted sperm analysis; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling; TCA, trichloroacetic acid; TBA, thiobarbituric acid; MDA, malondialdehyde; BTB, blood-testis barrier.

Author contributions

YS, ZW, and QZ designed the research study. BS performed the research. JJ collected samples. JX analyzed the data. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Donors were informed about the purpose of the study and their consent was obtained. The study was approved by the Ethics Committee of the Second Affiliated Hospital of Nanjing Medical University ([2019] KY 041).

Acknowledgment

We thank Liwen Bianji, Edanz Group (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

Funding

This research was funded by the National Natural Science Foundation of China (No. 81400758) and Science and technology development fund of Nanjing Medical University (NMUB2019048) for supporting our work.

Conflict of interest

The authors declare no conflict of interest.

References

- [1] Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. *European Journal of Pharmacology*. 2014; 740: 364–378.
- [2] Samplaski MK, Nangia AK. Adverse effects of common medications on male fertility. *Nature Reviews Urology*. 2015; 12: 401–413.
- [3] Fong CW. Platinum anti-cancer drugs: Free radical mechanism of Pt-DNA adduct formation and anti-neoplastic effect. *Free Radical Biology and Medicine*. 2016; 95: 216–229.
- [4] Ateşşahin A, Sahna E, Türk G, Ceribaşı AO, Yılmaz S, Yüce A, *et al.* Chemoprotective effect of melatonin against cisplatin-induced testicular toxicity in rats. *Journal of Pineal Research*. 2006; 41: 21–27.
- [5] Sikka SC. Oxidative stress and role of antioxidants in normal and abnormal sperm function. *Frontiers in Bioscience*. 2006; 11: e78–e86.
- [6] Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, Ramalingam SS, *et al.* Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. *PLoS ONE*. 2013; 8: e81162.
- [7] Chai R, Chen G, Shi H, O W, Martin-DeLeon PA, Chen H. Prohibitin involvement in the generation of mitochondrial superoxide at complex I in human sperm. *Journal of Cellular and Molecular Medicine*. 2017; 21: 121–129.
- [8] Eberl M, Schuppe H-, Kohn F-, Schill W-. Effect of two complex platinum salts on human sperm motility and acrosome reaction. *Andrologia*. 2000; 32: 303–310.
- [9] Parlakpınar H, Sahna E, Ozer MK, Ozugurlu F, Vardi N, Acet A. Physiological and pharmacological concentrations of melatonin protect against cisplatin-induced acute renal injury. *Journal of Pineal Research*. 2002; 33: 161–166.
- [10] Reiter RJ, Tan D, Sainz RM, Mayo JC, Lopez-Burillo S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. *The Journal of Pharmacy and Pharmacology*. 2002; 54: 1299–1321.

- [11] Saeedan AS, Soliman GA, Abdel-Rahman RF, Abd-Elsalam RM, Ogaly HA, Foudah AI, *et al.* Artemisia judaica L. diminishes diabetes-induced reproductive dysfunction in male rats via activation of Nrf2/HO-1-mediated antioxidant responses. *Saudi Journal of Biological Sciences*. 2021; 28: 1713–1722.
- [12] Shi S, Lei S, Tang C, Wang K, Xia Z. Melatonin attenuates acute kidney ischemia/reperfusion injury in diabetic rats by activation of the SIRT1/Nrf2/HO-1 signaling pathway. *Bioscience Reports*. 2019; 39: BSR20181614.
- [13] Gimeno-Martos S, Casao A, Yeste M, Cebrián-Pérez JA, Muñoz-Blanco T, Pérez-Pé R. Melatonin reduces cAMP-stimulated capacitation of ram spermatozoa. *Reproduction, Fertility and Development*. 2019; 31: 420.
- [14] Nagata O, Nakamura M, Sakimoto H, Urata Y, Sasaki N, Shiohawa N, *et al.* Mouse model of chorea-acanthocytosis exhibits male infertility caused by impaired sperm motility as a result of ultrastructural morphological abnormalities in the mitochondrial sheath in the sperm midpiece. *Biochemical and Biophysical Research Communications*. 2018; 503: 915–920.
- [15] Shao YP, Zhou Q, Li YP, Zhang SC, Xu HW, Wu S, *et al.* Curcumin ameliorates cisplatin-induced cystopathy via activating NRF2 pathway. *Neurourology and Urodynamics*. 2018; 37: 2470–2479.
- [16] Lopez-Gonzalez MA, Guerrero JM, Rojas F, Delgado F. Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. *Journal of Pineal Research*. 2000; 28: 73–80.
- [17] Calls A, Torres-Espin A, Navarro X, Yuste VJ, Udina E, Bruna J. Cisplatin-induced peripheral neuropathy is associated with neuronal senescence-like response. *Neuro-Oncology*. 2021; 23: 88–99.
- [18] Meena R, Kumari K, Kumar J, Rajamani P, Verma HN, Kesari KK. Therapeutic approaches of melatonin in microwave radiations-induced oxidative stress-mediated toxicity on male fertility pattern of Wistar rats. *Electromagnetic Biology and Medicine*. 2014; 33: 81–91.
- [19] Huang F, Ning H, Xin Q, Huang Y, Wang H, Zhang Z, *et al.* Melatonin pretreatment attenuates 2-bromopropane-induced testicular toxicity in rats. *Toxicology*. 2009; 256: 75–82.
- [20] Li B, He X, Zhuang M, Niu B, Wu C, Mu H, *et al.* Melatonin Ameliorates Busulfan-Induced Spermatogonial Stem Cell Oxidative Apoptosis in Mouse Testes. *Antioxidants & Redox Signaling*. 2018; 28: 385–400.
- [21] Kelnar CJH, McKinnell C, Walker M, Morris KD, Wallace WHB, Saunders PTK, *et al.* Testicular changes during infantile 'quiescence' in the marmoset and their gonadotrophin dependence: a model for investigating susceptibility of the prepubertal human testis to cancer therapy? *Human Reproduction*. 2002; 17: 1367–1378.
- [22] Smart E, Lopes F, Rice S, Nagy B, Anderson RA, Mitchell RT, *et al.* Chemotherapy drugs cyclophosphamide, cisplatin and doxorubicin induce germ cell loss in an in vitro model of the prepubertal testis. *Scientific Reports*. 2018; 8: 1773.
- [23] Wang C, Xia Y, Nie J, Zhou M, Zhang R, Niu L, *et al.* Musca domestica larva lectin induces apoptosis in BEL-7402 cells through a Ca(2+)/JNK-mediated mitochondrial pathway. *Cell Biochemistry and Biophysics*. 2013; 66: 319–329.
- [24] Jiang L, Cheng L, Kong S, Yang Y, Shen Y, Chen C, *et al.* Toxic effects of polychlorinated biphenyls (Aroclor 1254) on human sperm motility. *Asian Journal of Andrology*. 2017; 19: 561–566.
- [25] Bejarano I, Monllor F, Marchena AM, Ortiz A, Lozano G, Jiménez MI, *et al.* Exogenous melatonin supplementation prevents oxidative stress-evoked DNA damage in human spermatozoa. *Journal of Pineal Research*. 2014; 57: 333–339.
- [26] Pereira R, Sá R, Barros A, Sousa M. Major regulatory mechanisms involved in sperm motility. *Asian Journal of Andrology*. 2017; 19: 5–14.
- [27] Delamirande E, Cagnon C. Human sperm hyperactivation and capacitation as parts of an oxidative process. *Free Radical Biology and Medicine*. 1993; 14: 157–166.